Comparisons of basic target-mediated drug disposition (TMDD) and ligand facilitated target removal (LFTR)

被引:2
作者
Peletier, Lambertus A. [1 ]
Jansson-Lofmark, Rasmus [2 ]
Gabrielsson, Johan [3 ]
机构
[1] Leiden Univ, Math Inst, PB 9512, NL-2300 RA Leiden, Netherlands
[2] AstraZeneca, BioPharmaceut R&D, Res & Early Dev Cardiovasc Renal & Metab, DMPK, Gothenburg, Sweden
[3] Firma Biopharmacon, Engelbrektsgatan 5, S-41127 Gothenburg, Sweden
关键词
Drug disposition; Drug recycling; Target turnover; TMDD; Target removal; ALDOSE REDUCTASE; IN-VIVO; PHARMACOKINETIC MODEL; DEGRADATION;
D O I
10.1016/j.ejps.2021.105835
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the well-known model for basic Target-Mediated Drug Disposition (TMDD), drug binds to the target and the resulting drug-target complex is removed by a first order process, leading to loss of both drug and target. In the present note we study what happens when, instead, drug is returned to the free drug pool so that it can a new target molecule. What results is a mechanism in which the drug, here referred to as the ligand, facilitates the removal of the target,and then returns to the free ligand pool. Accordingly the process will be referred to as Ligand-Facilitated Target Removal (LFTR). It is shown through simulations and mathematical analysis how the two models differ and how their signature profiles typically appear. We also derive a useful parameter of both models, the in vivo potency EC50 (L50) which contains both ligand-target binding properties (kon, koff), target turnover (kdeg) and ligand-target complex kinetics (ke(RL)). Thus, this parameter contains a conglomerate of properties and is therefore potentially more informative about relevant (clinical) exposure than the binding affinity (Kd) alone. The derived potency parameter EC50 may therefore be used as a more robust ranking parameter among small and large drug molecules in drug discovery. Subsequently the LFTR model is applied to experimentally obtained literature data and the relevant parameters are estimated.
引用
收藏
页数:11
相关论文
共 26 条
  • [1] The Application of Target Information and Preclinical Pharmacokinetic/Pharmacodynamic Modeling in Predicting Clinical Doses of a Dickkopf-1 Antibody for Osteoporosis
    Betts, Alison M.
    Clark, Tracey H.
    Yang, Jianxin
    Treadway, Judith L.
    Li, Mei
    Giovanelli, Michael A.
    Abdiche, Yasmina
    Stone, Donna M.
    Paralkar, Vishwas M.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 333 (01) : 2 - 13
  • [2] DOSE-DEPENDENT PHARMACOKINETICS OF THE ALDOSE REDUCTASE INHIBITOR IMIRESTAT IN MAN
    BRAZZELL, RK
    MAYER, PR
    DOBBS, R
    MCNAMARA, PJ
    TENG, RL
    SLATTERY, JT
    [J]. PHARMACEUTICAL RESEARCH, 1991, 8 (01) : 112 - 118
  • [3] Small-Molecule Modulation of Protein Homeostasis
    Burslem, George M.
    Crews, Craig M.
    [J]. CHEMICAL REVIEWS, 2017, 117 (17) : 11269 - 11301
  • [4] Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9
    Chaparro-Riggers, Javier
    Liang, Hong
    DeVay, Rachel M.
    Bai, Lanfang
    Sutton, Janette E.
    Chen, Wei
    Geng, Tao
    Lindquist, Kevin
    Casas, Meritxell Galindo
    Boustany, Leila M.
    Brown, Colleen L.
    Chabot, Jeffrey
    Gomes, Bruce
    Garzone, Pamela
    Rossi, Andrea
    Strop, Pavel
    Shelton, Dave
    Pons, Jaume
    Rajpal, Arvind
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (14) : 11090 - 11097
  • [5] Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
    Churcher, Ian
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (02) : 444 - 452
  • [6] Gabrielsson J., 2016, PHARMACOKINETIC PHAR
  • [7] Michaelis-Menten from an In Vivo Perspective: Open Versus Closed Systems
    Gabrielsson, Johan
    Peletier, Lambertus A.
    [J]. AAPS JOURNAL, 2018, 20 (06):
  • [8] In vivo potency revisited - Keep the target in sight
    Gabrielsson, Johan
    Peletier, Lambertus A.
    Hjorth, Stephan
    [J]. PHARMACOLOGY & THERAPEUTICS, 2018, 184 : 177 - 188
  • [9] Pharmacokinetic Steady-States Highlight Interesting Target-Mediated Disposition Properties
    Gabrielsson, Johan
    Peletier, Lambertus A.
    [J]. AAPS JOURNAL, 2017, 19 (03): : 772 - 786
  • [10] Gibaldi M., 1982, Pharmacokinetics, V2nd ed.